Bio-Techne Corporation filings document the formal disclosure record for a Minnesota life sciences company that sells reagents, analytical instruments and precision diagnostics. Recent Form 8-K reports furnish quarterly and annual operating results, financial condition updates and cash dividend announcements, with exhibits containing the related earnings and dividend releases.
Governance filings include definitive proxy materials and annual meeting vote results covering board size and director elections. Other current reports disclose executive leadership changes and employment arrangements for segment management, tying corporate governance disclosures to Bio-Techne's diagnostics, spatial biology and analytical solutions operations.
Bio‑Techne (TECH): Form 4 insider update. Director Amy E. Herr reported an equity grant on 10/30/2025. She acquired 1,640 shares of common stock at $0, bringing direct holdings to 2,680 shares; an additional 2,154 shares are held indirectly by a significant other.
She was also granted a stock option to buy 3,777 shares at $60.96, expiring 10/30/2035; vesting occurs on the earlier of the one‑year anniversary of the grant or the 2026 annual meeting. The filing also lists previously awarded options and restricted stock units held indirectly with specified vesting schedules.
Bio‑Techne (TECH) director Judith V. Klimovsky filed a Form 4 reporting equity awards. On 10/30/2025, she acquired 1,640 shares of common stock at $0, bringing direct holdings to 3,782 shares.
She was also granted a stock option for 3,777 shares at an exercise price of $60.96, expiring 10/30/2035. The option vests on the earlier of the one year anniversary of the grant date (10/30/2025) or the date of Bio‑Techne’s 2026 annual meeting of shareholders. Existing options include 1,610 at $73.46 (exp. 05/01/2034) and 3,511 at $68.37 (exp. 10/24/2034).
Bio‑Techne (TECH) reported an insider equity update. A director acquired 1,640 shares of common stock on 10/30/2025 at a reported price of $0, bringing direct beneficial ownership to 10,987 shares after the transaction.
The filing also lists a new derivative award: 3,777 stock options acquired on 10/30/2025 with an exercise price of $60.96 and an expiration date of 10/30/2035. According to the footnote, the option vests on the earlier of the one‑year anniversary of the grant date (10/30/2025) or the date of Bio‑Techne’s 2026 annual meeting of shareholders.
Bio‑Techne (TECH) director Robert V. Baumgartner reported insider activity. On 10/30/2025, he acquired 1,640 common shares at $0, bringing his directly held shares to 46,503 after the transaction. He was also granted a stock option for 3,777 shares at an exercise price of $60.96, expiring on 10/30/2035. The option vests on the earlier of the one‑year anniversary of the grant date or the company’s 2026 annual meeting of shareholders.
Bio-Techne reshaped its portfolio in fiscal 2025, selling the Exosome Diagnostics business (including the ExoDx Prostate test and related CLIA lab) to Mdxhealth SA and retaining access to the exosome technology for continued kit development. The company introduced over 500 new products in fiscal 2025, including the next-generation Simple Western instrument Leo, ProPak GMP Cytokines, the QuantideX ESR1 exoMutation Kit, and AI-designed proteins, and announced a new EMEA Customer Service Center with a Demonstration Laboratory targeted to launch in summer 2026.
Corporate governance and compensation were updated: the Board maintains separate Chair/CEO roles, independent committees, shareholder rights (proxy access, special meeting rights), and director tenure/retirement policies; compensation changes include adding relative TSR as a metric, a new equity mix (50% performance RSUs, 25% time RSUs, 25% options), and adjusted bonus payout bands. Reported company metrics show market capitalization $11.51B, revenues of $1.15B, adjusted EBITA of $257.4M, and an annualized 3-year TSR of -10% versus peer medians.
Roeland Nusse, a director of Bio-Techne Corporation (TECH), reported option exercises and share sales on 08/25/2025. He exercised 17,040 stock options with an exercise price of $21.84 and simultaneously sold 17,040 common shares at a weighted average price of $56.3608, reducing his reported beneficial ownership to 44,559 shares. Table II shows Nusse retains multiple outstanding option grants exercisable into common stock, including 17,040 options exercisable through 10/28/2025 and other option tranches with exercise prices from $25.30 to $128.81. The Form 4 was submitted via attorney-in-fact on 08/27/2025.
Robert V. Baumgartner, a director of Bio-Techne Corporation (TECH), reported transactions on 08/25/2025 in which he exercised 17,040 stock options with an exercise price of $21.84 and immediately sold 17,040 common shares at a weighted average price of $56.21 (sales ranged $55.97–$56.34). The Form 4 shows a temporary increase in beneficial ownership to 61,903 shares after the exercise, and a final beneficial ownership of 44,863 shares following the sale. The filing lists outstanding stock options across multiple grant years with strike prices from $21.84 to $128.81 and various expiration dates, and notes one option vests on the earlier of the one-year anniversary of the 10/24/2024 grant or Bio-Techne's 2025 annual meeting. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Baumgartner.
Form 144 filed for Bio-Techne Corp. (TECH) reports a proposed sale of 17,040 common shares via Morgan Stanley Smith Barney LLC on 08/25/2025. The filing shows an aggregate market value of $960,388.03 and notes 155,549,587 shares outstanding, indicating the sale represents a very small fraction of the company’s outstanding stock. The shares were acquired and paid for on 08/25/2025 through a stock option exercise paid in cash. The filer certifies they are not aware of undisclosed material adverse information. No other sales in the past three months are reported.
Form 144 notice for Bio-Techne Corp. (TECH) reports a proposed sale of 17,040 shares of common stock through Morgan Stanley Smith Barney with an aggregate market value of $957,849.07. The filing shows the shares outstanding are 155,549,587 and lists the approximate sale date as 08/25/2025 on NASDAQ. The securities were acquired on 08/25/2025 by exercise of options under a registered plan from the issuer and payment is shown as cash. The filer represents they are not aware of undisclosed material adverse information. Several identifying fields such as the filer name/CIK and issuer address are not provided in the text.
Bio-Techne (TECH) describes fiscal 2025 operational and strategic developments including portfolio expansion, tax attributes, and governance controls. The company reports 155,549,587 shares outstanding (post 4-for-1 split adjustment) and an independent opinion that it maintained effective internal control over financial reporting as of June 30, 2025 under the COSO 2013 framework.
Material acquisitions noted include Lunaphore acquired for $169.7 million (cash-free, debt-free) adding spatial biology instruments to Diagnostics and Spatial Biology, and Namocell acquired for $101.2 million net of cash plus up to $25 million contingent consideration, adding single-cell sorting platforms to Protein Sciences. The company recorded goodwill related to these deals that is not deductible for tax purposes. The filing discloses a $37.2 million arbitration settlement (inclusive of interest and fees) and an additional $0.5 million payment related to an options dispute.